BACKGROUND: Patients with ulcerative colitis (UC) are at risk of developing colorectal cancer. We have previously reported that cancer progression is associated with the presence of clonal expansions and shorter telomeres in nondysplastic mucosa. We sought to validate these findings in an independent case-control study. METHODS: This study included 33 patients with UC: 14 progressors (patients with high-grade dysplasia or cancer) and 19 nonprogressors. For each patient, a mean of 5 nondysplastic biopsies from proximal, mid, and distal colon were assessed for clonal expansions, as determined by clonal length altering mutations in polyguanine tracts, and telomere length, as measured by quantitative PCR. Both parameters were compared with individual clinicopathological characteristics. RESULTS: Clonal expansions and shorter telomeres were more frequent in nondysplastic biopsies from UC progressors than nonprogressors, but only for patients with early-onset of UC (diagnosis at younger than 50 years of age). Late-onset progressor patients had very few or no clonal expansions and longer telomeres. A few nonprogressors exhibited clonal expansions, which were associated with older age and shorter telomeres. In progressors, clonal expansions were associated with proximity to dysplasia. The mean percentage of clonally expanded mutations distinguished early-onset progressors from nonprogressors with 100% sensitivity and 80% specificity. CONCLUSIONS: Early-onset progressors develop cancer in a field of clonally expanded epithelium with shorter telomeres. The detection of these clones in a few random nondysplastic colon biopsies is a promising cancer biomarker in early-onset UC. Curiously, patients with late-onset UC seem to develop cancer without the involvement of such fields.
BACKGROUND:Patients with ulcerative colitis (UC) are at risk of developing colorectal cancer. We have previously reported that cancer progression is associated with the presence of clonal expansions and shorter telomeres in nondysplastic mucosa. We sought to validate these findings in an independent case-control study. METHODS: This study included 33 patients with UC: 14 progressors (patients with high-grade dysplasia or cancer) and 19 nonprogressors. For each patient, a mean of 5 nondysplastic biopsies from proximal, mid, and distal colon were assessed for clonal expansions, as determined by clonal length altering mutations in polyguanine tracts, and telomere length, as measured by quantitative PCR. Both parameters were compared with individual clinicopathological characteristics. RESULTS: Clonal expansions and shorter telomeres were more frequent in nondysplastic biopsies from UC progressors than nonprogressors, but only for patients with early-onset of UC (diagnosis at younger than 50 years of age). Late-onset progressor patients had very few or no clonal expansions and longer telomeres. A few nonprogressors exhibited clonal expansions, which were associated with older age and shorter telomeres. In progressors, clonal expansions were associated with proximity to dysplasia. The mean percentage of clonally expanded mutations distinguished early-onset progressors from nonprogressors with 100% sensitivity and 80% specificity. CONCLUSIONS: Early-onset progressors develop cancer in a field of clonally expanded epithelium with shorter telomeres. The detection of these clones in a few random nondysplastic colon biopsies is a promising cancer biomarker in early-onset UC. Curiously, patients with late-onset UC seem to develop cancer without the involvement of such fields.
Authors: Joseph B Hiatt; Colin C Pritchard; Stephen J Salipante; Brian J O'Roak; Jay Shendure Journal: Genome Res Date: 2013-02-04 Impact factor: 9.043
Authors: T A Brentnall; D A Crispin; P S Rabinovitch; R C Haggitt; C E Rubin; A C Stevens; G C Burmer Journal: Gastroenterology Date: 1994-08 Impact factor: 22.682
Authors: Rosa Ana Risques; Lisa A Lai; Cigdem Himmetoglu; Anoosheh Ebaee; Lin Li; Ziding Feng; Mary P Bronner; Bassel Al-Lahham; Kris V Kowdley; Keith D Lindor; Peter S Rabinovitch; Teresa A Brentnall Journal: Cancer Res Date: 2011-03-01 Impact factor: 12.701
Authors: Boudewijn J M Braakhuis; Maarten P Tabor; J Alain Kummer; C René Leemans; Ruud H Brakenhoff Journal: Cancer Res Date: 2003-04-15 Impact factor: 12.701
Authors: Jason K Hou; Jennifer R Kramer; Peter Richardson; Minghua Mei; Hashem B El-Serag Journal: Inflamm Bowel Dis Date: 2013-04 Impact factor: 5.325
Authors: J E Baars; E J Kuipers; M van Haastert; J J Nicolaï; A C Poen; C J van der Woude Journal: J Gastroenterol Date: 2012-05-25 Impact factor: 7.527
Authors: Chang-Ho R Choi; Ibrahim Al Bakir; Ailsa L Hart; Trevor A Graham Journal: Nat Rev Gastroenterol Hepatol Date: 2017-02-08 Impact factor: 46.802
Authors: Kathryn T Baker; Daniela Nachmanson; Shilpa Kumar; Mary J Emond; Cigdem Ussakli; Teresa A Brentnall; Scott R Kennedy; Rosa Ana Risques Journal: Mol Cancer Res Date: 2018-11-16 Impact factor: 5.852
Authors: Mariann Friis-Ottessen; Laila Bendix; Steen Kølvraa; Solveig Norheim-Andersen; Paula M De Angelis; Ole Petter F Clausen Journal: BMC Gastroenterol Date: 2014-01-09 Impact factor: 3.067
Authors: Mariann Friis-Ottessen; Paula M De Angelis; Aasa R Schjølberg; Solveig N Andersen; Ole Petter F Clausen Journal: Int J Mol Med Date: 2014-03-20 Impact factor: 4.101
Authors: Mariann Friis-Ottessen; Espen Burum-Auensen; Aasa R Schjølberg; Per Olaf Ekstrøm; Solveig N Andersen; Ole Petter Clausen; Paula M De Angelis Journal: Int J Mol Med Date: 2014-10-20 Impact factor: 4.101
Authors: Yuezheng Zhang; Brendan F Kohrn; Ming Yang; Daniela Nachmanson; T Rinda Soong; I-Hsiu Lee; Yong Tao; Hans Clevers; Elizabeth M Swisher; Teresa A Brentnall; Lawrence A Loeb; Scott R Kennedy; Jesse J Salk; Kamila Naxerova; Rosa Ana Risques Journal: Proc Natl Acad Sci U S A Date: 2021-08-03 Impact factor: 11.205